Bookmark
Forward
QuickView for milrinone (compound)
PubChem
| Name: | Milrinone |
|---|---|
| PubChem Compound ID: | 172293 |
| Description: | A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone. |
| Molecular formula: | C15H15N3O4 |
| Molecular weight: | 301.297 g/mol |
| Synonyms: |
100286-97-3; D02085; C13595; Primacor; Propanoic acid, 2-hydroxy-, compd. with 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; Primacor (TN); Milrinone lactate; 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile, compd. with 2-hydroxypropionic acid
|
DrugBank
Identification
| Name: | Milrinone |
|---|---|
| Name (isomeric): | DB00235 |
| Drug Type: | small molecule |
| Description: | A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone. |
| Synonyms: |
Milrinone Lactate
|
| Brand: | Milrila, Corotrop, Primacor, Corotrope |
| Category: | Vasodilator Agents, Phosphodiesterase Inhibitors, Cardiotonic Agents, Platelet Aggregation Inhibitors |
| CAS number: | 78415-72-2 |
Pharmacology
| Indication: | Indicated for the treatment of congestive heart failure. |
|---|---|
| Pharmacology: | Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
| Mechanism of Action: | Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. |
| Absorption: | Milrinone is rapidly and almost completely absorbed after oral administration. Bioavailability is 92% (in healthy volunteers). |
| Protein binding: | 70 to 80% |
| Biotransformation: | There are five metabolites but the O-glucuronide represents the major pathway of biotransformation. |
| Route of elimination: | The primary route of excretion of milrinone in man is via the urine. |
| Half Life: | 2.3 hours |
| Clearance: | 0.13 L/kg/hr [congestive heart failure patients, following IV injections of 12.5 mcg/kg to 125 mcg/kg] 0.14 L/kg/hr [congestive heart failure patients, following infusions of 0.2 mcg/kg/min to 0.7 mcg/kg/min] |
| Toxicity: | LD50 = 0.3 mg/L in rats |
| Affected organisms: | Humans and other mammals |
Targets
